Erlotinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ERLOTINIB |
|---|---|
| Type | Drug |
| Aliases | TarcevaЕрлотиніб |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | 1st-generation EGFR TKI (reversible) |
|---|---|
| Mechanism | Reversible EGFR-TKI. Pre-T790M era 1L standard; now 2L+ or alternate when osimertinib unavailable. |
| Typical dosing | 150 mg PO once daily on empty stomach. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Largely supplanted by osimertinib in 1L. 2L+ option when osi-resistance pathway not amenable to next-line targeted; rare in modern era.
Used By
No reverse references found in the YAML corpus.